- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 29.07. | MapLight CEO on what investors missed in the biotech's schizophrenia data | 3 | BioPharma Dive | ||
| 28.07. | MapLight Therapeutics recovers a portion of Monday's 73% rout | 1 | Seeking Alpha | ||
| 28.07. | BMO cuts MapLight Therapeutics price target on trial results | 1 | Investing.com | ||
| 28.07. | Canaccord cuts MapLight Therapeutics stock price target on trial data | 1 | Investing.com | ||
| 28.07. | H.C. Wainwright cuts MapLight Therapeutics stock price target on trial results | 1 | Investing.com | ||
| 27.07. | Morgan Stanley downgrades MapLight Therapeutics stock rating on trial results | 19 | Investing.com | ||
| MAPLIGHT THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 27.07. | Enttäuschende Studiendaten: Morgan Stanley stuft MapLight Therapeutics ab | 9 | Investing.com Deutsch | ||
| 27.07. | Wolfe cuts MapLight Therapeutics stock price target on trial data | 1 | Investing.com | ||
| 27.07. | MapLight dives despite positive data for schizophrenia drug | 2 | BioPharma Dive | ||
| 27.07. | MapLight shares sink on mixed phase 2 schizophrenia readout | 1 | FierceBiotech | ||
| 27.07. | MapLight Therapeutics Stock Falls Despite Schizophrenia Drug Meeting Main Trial Goal | 1 | Benzinga.com | ||
| 27.07. | MapLight Therapeutics: TD Cowen bestätigt Kaufempfehlung nach Studiendaten | 3 | Investing.com Deutsch | ||
| 27.07. | Raymond James cuts MapLight Therapeutics stock price target on efficacy data | 1 | Investing.com | ||
| 27.07. | Jefferies reiterates MapLight Therapeutics stock rating on trial data | 1 | Investing.com | ||
| 27.07. | Jefferies bestätigt Kaufempfehlung für MapLight Therapeutics nach Studiendaten | 3 | Investing.com Deutsch | ||
| 27.07. | BMO reiterates Outperform on MapLight stock after trial data | 2 | Investing.com | ||
| 27.07. | MapLight Reports Results From Phase 2 ZEPHYR Trial Of ML-007C-MA; Stock Down More Than 60% | 17 | RTTNews | ||
| 27.07. | Stifel reiterates MapLight Therapeutics stock rating on schizophrenia data | 2 | Investing.com | ||
| 27.07. | MapLight Therapeutics stock tumbles 50% on mixed phase 2 schizophrenia data | 2 | Seeking Alpha | ||
| 27.07. | MapLight schizophrenia drug meets phase 2 trial primary endpoint | 1 | Investing.com |
1 2 3 Weiter >>
60 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AMGEN | 355,85 | +0,13 % | Ihre wichtigsten Termine: Q2-Updates von SpaceX, Bayer, Biontech, Spotify, Pfizer, Continental, Merck & Co | © Foto: Dall-EGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Untermehmenstermine 05:00 Uhr, Großbritannien:... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 46,430 | +0,32 % | CRISPR Therapeutics AG: CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results | ZUG, Switzerland and BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the second quarter ended June 30, 2026. "The second quarter reflected... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 0,580 | +1,05 % | Inovio Pharmaceuticals, Inc.: INOVIO Announces Pricing of $20.0 Million Public Offering | PLYMOUTH MEETING, Pa., July 29, 2026 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing... ► Artikel lesen | |
| INFLARX | 1,585 | -0,69 % | InflaRx N.V.: InflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones | Announced advancement of izicopan in ANCA-associated vasculitis (AAV) and select renal diseases; clinical preparations ongoing as plannedInitiated feasibility assessment for broadened strategy for... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 10,300 | -0,39 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates | Positive Phase 3 HAELO clinical data for lonvo-z in HAE presented at EAACI and published in New England Journal of MedicineAnticipate FDA acceptance of BLA for lonvo-z in second half of 2026 and U.S.... ► Artikel lesen | |
| IBIO | 1,264 | +3,27 % | iBio, Inc.: iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer | SAN DIEGO, Aug. 04, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary... ► Artikel lesen | |
| IMMUNITYBIO | 6,550 | -0,76 % | IBRX Q2 Earnings & Sales Beat Estimates on Strong Anktiva Uptake | ||
| IMMATICS | 8,280 | +2,92 % | Immatics Announces Upcoming Presentations Across Its PRAME Franchise at ESMO Congress 2026 | Houston, Texas and Tuebingen, Germany, July 17, 2026 - Immatics N.V. (NASDAQ: IMTX, "Immatics" or the "Company"), the global leader in precision targeting of PRAME with multiple clinical-stage programs... ► Artikel lesen | |
| MANNKIND | 3,540 | 0,00 % | H.C. Wainwright reiterates Buy rating on MannKind stock at $10 | ||
| IMMUNIC | 13,180 | +6,59 % | EQS-News: Immunic AG: Immunic to Participate in Investor Conferences in July | Issuer: Immunic AG
/ Key word(s): Conference
Immunic to Participate in Investor Conferences in July
09.07.2026 / 12:30 CET/CEST
The issuer is solely responsible for... ► Artikel lesen | |
| IOVANCE BIOTHERAPEUTICS | 5,500 | +0,36 % | Iovance Biotherapeutics, Inc.: Iovance Biotherapeutics Reports Record Second Quarter 2026 Revenue of ~$99M, Business Achievements, and Corporate Updates | U.S. Amtagvi Revenue Reaches ~$91M and Total Revenue Increased 66% Year-over-Year Gross Margin Increased to 56% Fast Track Designation (FTD) Granted by the FDA for Lifileucel in Soft Tissue Sarcomas... ► Artikel lesen | |
| MOLECULIN BIOTECH | 0,409 | -0,10 % | Moleculin Biotech, Inc.: Moleculin Announces Pricing of $9.3 Million Public Offering | HOUSTON, July 31, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), today announced the pricing of a best-efforts public offering of an aggregate of... ► Artikel lesen | |
| GENPREX | 4,300 | +0,70 % | Genprex, Inc.: Genprex Announces Collaboration with Roche Diagnostics for Biomarker Assay Validation Studies | Collaboration Advances Biomarker-Driven Patient Selection and Precision Medicine in Oncology
Validation Studies Aim to Optimize Clinical Trial Patient Selection... ► Artikel lesen | |
| MACROGENICS | 3,360 | -4,00 % | MacroGenics, Inc.: MacroGenics Provides Clinical Update on Ongoing Phase 1 Study for MGC026 | Interim Phase 1 results accepted for poster presentation at ESMO Congress 2026Achieved pre-specified Stage 1 response threshold in squamous cell carcinoma of the head and neck (SCCHN) cohort and enrolling... ► Artikel lesen | |
| MESOBLAST | 1,380 | +1,36 % | Mesoblasts führende Zelltherapie erzielt im ersten vollständigen Verkaufsjahr einen Umsatz von 115 Mio. US-Dollar |
Das Unternehmen MAPLIGHT THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 12,210 Euro und damit +0,33 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MAPLIGHT THERAPEUTICS INC finden Sie auf Wallstreet Online.